Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
Berruti A, Bitossi R, Gorzegno G, Bottini A, Alquati P, De Matteis A, Nuzzo F, Giardina G, Danese S, De Lena M, Lorusso V, Farris A, Sarobba MG, DeFabiani E, Bonazzi G, Castiglione F, Bumma C, Moro G, Bruzzi P, Dogliotti L; Epirubicin-Lonidamine Group, Orbassano, Torino, Italy.
Berruti A, et al. Among authors: bumma c.
J Clin Oncol. 2002 Oct 15;20(20):4150-9. doi: 10.1200/JCO.2002.08.012.
J Clin Oncol. 2002.
PMID: 12377958
Clinical Trial.